Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

Fig. 3

Long-term survival. ab Overall survival (a) and relapse-free survival (b) of the 20 R/R B-ALL patients treated with the CNCT19 CAR T cell infusion. Overall survival (c) and relapse-free survival (d) of patients who underwent hematopoietic stem cell transplantation. Overall survival (e) or relapse-free survival (f) of both pediatric and adult patients

Back to article page